Long-acting injectables eliminate this problem by providing steady medication levels for weeks or months from a single administration
However, anti-obesity medications are prescribed to only about 4% of eligible people due to concerns about safety or effectiveness, lack of health care provider training in weight management, excessive costs due to insurance companies refusing coverage, and a toxic stigma that portrays obesity as a lack of willpower
Clinical trial data for GLP-1 medicines, including Ozempic, Mounjaro, Wegovy/Wegovy HD, Zepbound, and Foundayo, were reviewed to compare reported weight-loss results, FDA-approved uses, and study limitations
Liposomal delivery wraps glutathione in a phospholipid shell to improve its stability and absorption compared to standard oral forms
advertising spend on GLP-1 drugs in the first nine months of 2025, while noting Canada enforces stricter direct-to-consumer drug advertising regulations
PAH, Pulmonary arterial hypertension